FCGR3A Inhibitors
1 drugsAbout FCGR3A
FCGR3A (Fc gamma receptor IIIa) is a receptor for the Fc region of IgG antibodies, crucial for antibody-dependent cell-mediated cytotoxicity (ADCC). It enables immune cells to recognize and kill antibody-coated tumor cells, enhancing anti-cancer immune responses.
FCGR3A is a therapeutic target to enhance antibody-based cancer treatments by modulating interactions between antibodies and immune cells. Currently, there is no genetic evidence data available linking FCGR3A to disease susceptibility or treatment response.
FCGR3A is targeted by one FDA-approved biologic drug, MARGENZA, in oncology. MacroGenics Inc. is the only company with an approved drug, first approved in 2020.
Top FCGR3A Drugs
MacroGenics Inc. is the only company with an approved drug targeting FCGR3A.
The market is highly concentrated, suggesting high barriers to entry or a first-mover advantage for MacroGenics.
FCGR3A Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FCGR3A, using biologic (other) modality.
The lack of small molecule or other modalities indicates a whitespace opportunity for novel therapeutic approaches.
FCGR3A Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FCGR3A. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 4 | 0 | 0 | 100% |
| Phase 2 | 4 | 2 | 1 | 1 | 67% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FCGR3A Drug Approval Timeline (2020 - 2020)
The first and only drug targeting FCGR3A, MARGENZA, was approved in 2020.
Recent approval suggests growing interest, but limited timeline indicates potential for further market development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FCGR3A. A trial counts if an approved drug acting on FCGR3A is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.